Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
11/1/24 | Novo Nordisk (NVO) | Semaglutide (NASH) for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
10/31/24 | Lexicon Pharmaceuticals (LXRX) | Inpefa for Diabetes Mellitus, Type I | Subscribers Only | Subscribers Only | Subscribers Only |
10/29/24 | GlycoMimetics (GLYC) | Uproleselan for Acute Myelogenous Leukemia (AML) | Subscribers Only | Subscribers Only | Subscribers Only |
10/29/24 | Lexicon Pharmaceuticals (LXRX) | Inpefa for Diabetes Mellitus, Type I | Subscribers Only | Subscribers Only | Subscribers Only |
10/29/24 | Shionogi (4507) | Xocova for COVID-19 Prevention | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/01/2025 - 04/30/2024 | Subscribers Only | Subscribers Only | Trial Announcement - Data Monitoring Board Analysis |
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/16/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/30/2024 | Subscribers Only | Subscribers Only | Progress Update - Development Review |
11/05/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |